Florastamin clinical trials
How each study uses florastamin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- [F-18]Florastamin
- 2
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses florastamin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate CancerCompletedPhase 3HTA Co., Ltd.NCT06011304Written as [18F]Florastamin InjectionHow we know
- [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate CancerActive, not recruitingPhase 3FutureChemNCT05936658Written as [F-18]FlorastaminHow we know
- Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI DiagnosisActive, not recruitingPhase 3FutureChemNCT05004285Written as [F-18]FlorastaminHow we know